Jeyou Pharmaceuticals - Jeyou Pharmaceutical Technology Co., Ltd.

About Us

Science and Medicine

Production and Quality

Global Operations

News

Career Development

Contact Us

get in touch

Phone number

400-9963695

Email

PR@jeyoupharma.com

Address

Jimin Kexin (Shanghai) Pharmaceutical Industrial Park, Lane 535, Huanqiao Road, Pudong New Area, Shanghai, China

About Us

Company Profile History Business Philosophy Company Honors

Science and Medicine

Science and Medicine R&D System R&D Team R&D Platform Pipe Layout Pharmacovigilance

Production and Quality

Manufacturing facility Quality Management System

Global Operations

Commercialization Global Collaboration

News

Company News

Career Development

Talent Philosophy Employee Development

Contact Us

Contact Us Adverse Event Reporting

Innovation and R&D

Technology Empowers Life: Exploring New Frontiers in the Future of Medicine

Smart Manufacturing

Smart Manufacturing and Lean Production: Upholding Our Commitment to the Safety of Every Pill

Caring for Patients

Patient-centered care: Caring for patients and spreading smiles

A Happy Life

Health is the foundation of happiness; let’s work together to build a brighter future.

Committed to becoming a modern, innovative pharmaceutical company that is internationally advanced and a leader in China

Shanghai Jeyou Pharmaceutical Technology Co., Ltd. specializes in the research, development, manufacturing, and commercialization of innovative drugs. Leveraging its exceptional drug development capabilities and integrated research, production, and sales model, Jeyou Pharmaceutical is committed to rapidly bringing its proprietary innovative drugs to the global market to address unmet medical needs.

Discover Jeyou

Focusing on 3+1 core therapeutic areas

Building an innovative drug R&D pipeline

R&D Platform

Through iterative development using an AI platform, Jiyu Pharmaceutical has established five R&D platforms that feature exceptionally high competitive barriers and efficiency.

Explore more

Focusing on 3+1 Core Therapeutic Areas

Building an Innovative Drug R&D Pipeline

Disease Areas

Jiyu Pharmaceuticals is clinically value-driven and focuses on a “3+1” indication matrix encompassing oncology, nephrology, pain management, and autoimmune diseases.

Explore more

Focusing on 3+1 Core Therapeutic Areas

Building an Innovative Drug R&D Pipeline

R&D Pipeline

There are currently more than 40 projects in development, 19 of which have entered the clinical trial phase both domestically and internationally.

Explore more

Focusing on 3+1 Core Therapeutic Areas

Building an Innovative Drug R&D Pipeline

R&D Team

Jiyu Pharmaceuticals currently employs over 500 R&D staff, 20% of whom hold PhDs, and its core team of scientists each has over 15 years of experience in drug development.

Explore more

R&D Platform

Disease Areas

R&D Pipeline

R&D Team

R&D Platform

Disease Areas

R&D Pipeline

R&D Team

Global Collaboration

Jeyou Pharma has successfully transferred the overseas rights to intellectual property for several innovative drugs, entering into licensing agreements with multinational pharmaceutical companies such as Huya Bio International, ORION, Genentech (a subsidiary of Roche), and RAPT. These efforts have effectively enhanced the influence of Chinese pharmaceutical companies in the global innovative drug sector.

News
Stay informed about corporate developments and industry trends

Validating a Comprehensive R&D System and Pioneering New Frontiers in Combination Therapies | Jeyou Pharma’s First Class 1 Innovative Drug, Jielemei®, Approved for Market Launch

Validating a Comprehensive R&D System and Pioneering New Frontiers in Combination Therapies | Jeyou Pharma’s First Class 1 Innovative Drug, Jielemei®, Approved for Market Launch

Breaking News | $2.2 Billion! GSK Sets Sights on Jeyou’s Core Asset JYB1904; Roche and GSK Demonstrate Dual Breakthroughs in “Small and Large Molecules”

Breaking News | $2.2 Billion! GSK Sets Sights on Jeyou’s Core Asset JYB1904; Roche and GSK Demonstrate Dual Breakthroughs in “Small and Large Molecules”

Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, Led a Delegation on a Visit to Jeyou Pharmaceutical: Government and Enterprise Join Forces to Chart a Course for Innovation in the Biopharmaceuti

Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, Led a Delegation on a Visit to Jeyou Pharmaceutical: Government and Enterprise Join Forces to Chart a Course for Innovation in the Biopharmaceuti

Jeyou Pharma and RAPT Therapeutics Jointly Announce Positive Top-Line Results from the Phase 2 Clinical Trial of JYB1904 (RPT904) for the Treatment of Chronic Spontaneous Urticaria

Jeyou Pharma and RAPT Therapeutics Jointly Announce Positive Top-Line Results from the Phase 2 Clinical Trial of JYB1904 (RPT904) for the Treatment of Chronic Spontaneous Urticaria

Validating a Comprehensive R&D System and Pioneering New Frontiers in Combination Therapies | Jeyou Pharma’s First Class 1 Innovative Drug, Jielemei®, Approved for Market Launch

Validating a Comprehensive R&D System and Pioneering New Frontiers in Combination Therapies | Jeyou Pharma’s First Class 1 Innovative Drug, Jielemei®, Approved for Market Launch

Breaking News | $2.2 Billion! GSK Sets Sights on Jeyou’s Core Asset JYB1904; Roche and GSK Demonstrate Dual Breakthroughs in “Small and Large Molecules”

Breaking News | $2.2 Billion! GSK Sets Sights on Jeyou’s Core Asset JYB1904; Roche and GSK Demonstrate Dual Breakthroughs in “Small and Large Molecules”

Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, Led a Delegation on a Visit to Jeyou Pharmaceutical: Government and Enterprise Join Forces to Chart a Course for Innovation in the Biopharmaceuti

Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, Led a Delegation on a Visit to Jeyou Pharmaceutical: Government and Enterprise Join Forces to Chart a Course for Innovation in the Biopharmaceuti

Jeyou Pharma and RAPT Therapeutics Jointly Announce Positive Top-Line Results from the Phase 2 Clinical Trial of JYB1904 (RPT904) for the Treatment of Chronic Spontaneous Urticaria

Jeyou Pharma and RAPT Therapeutics Jointly Announce Positive Top-Line Results from the Phase 2 Clinical Trial of JYB1904 (RPT904) for the Treatment of Chronic Spontaneous Urticaria

Explore more